The European Medicines Agency has extended the indication for dapagliflozin for patients with type 1 diabetes, as well as type 2.  Still, these treatments have not been FDA approved for type 1 patients in the US. Two trials were conducted to assess how dapagliflozin performed when it was added to the medication regimen for a patient with type 1 diabetes. Read more